The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Toxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding
Open accessAbstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN, Lyell's syndrome) are now considered to be distinct clinical entities within a spectrum of adverse cutaneous drug reactions of increasing severity based on their surface of skin detachment. Within this spectrum, SJS which can be considered as a minor form of TEN is characterized by less than 10% body surface area of skin detachment, and an average reported mortality of 1-5%, whereas TEN is characterized by more than 30% skin detachment, and an average reported mortality 25-35%. Both SJS and TEN are characterized morphologically by the rapid onset of keratinocyte cell death by apoptosis, a process that results in the separation of the epidermis from the dermis. Recent evidence is supportive of a role for inflammatory cytokines and the death receptor Fas and its ligand FasL in the pathogenesis of keratinocyte apoptosis during TEN. This Fas-mediated keratinocyte apoptosis that is the last step culminating in epidermal detachment in TEN can be inhibited in vitro by antagonistic monoclonal antibodies to Fas, and by intravenous immunoglobulins (IVIG) which have been shown to contain natural anti-Fas antibodies. Consequently, over the last few years, numerous case reports and 9 non-controlled clinical studies containing 10 or more patients have analyzed the therapeutic effect of IVIG in TEN. Taken together, although each study has its potential biases, 7 of 9 such studies point towards a benefit of IVIG used at doses greater than 2 g/kg on the mortality associated with TEN. These studies should serve as the basis for designing an appropriate prospective trial or for conducting a metaanalysis in the near future, in order to determine the therapeutic efficacy of IVIG in TEN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Bastuji‐Garin, S. (1993) · Archives of Dermatology · doi:10.1001/archderm.129.1.92 · Cited by 1,697
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,199
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Self-citationInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
TOXIC EPIDERMAL NECROLYSIS: AN ERUPTION RESEMBLING SCALDING OF THE SKIN.
LYELL, A. (1956) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1956.tb12766.x · Cited by 720
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M., & Roujeau, J.-C. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.047 · Cited by 412
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients
Revuz, J. E. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.9.1160 · Cited by 395
Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985
Roujeau, J. (1990) · Archives of Dermatology · doi:10.1001/archderm.126.1.37 · Cited by 391
Toxic epidermal necrolysis (Lyell syndrome)
Roujeau, J.-C., Chosidow, O., Saiag, P., & Guillaume, J.-C. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70333-d · Cited by 383
Bachot, N., Revuz, J., & Roujeau, J.-C. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.33 · Cited by 380
Pereira, F. A., Mudgil, A. V., & Rosmarin, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.048 · Cited by 376
Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
SHEAR, N. H., SPIELBERG, S. P., GRANT, D. M., TANG, B. K., & KALOW, W. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-2-179 · Cited by 373
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., et al. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.26 · Cited by 325
Self-citationToxic Epidermal Necrolysis (Lyell Syndrome): Incidence and Drug Etiology in France, 1981-1985
Roujeau, J.-C. (1990) · Archives of Dermatology · doi:10.1001/archderm.1990.01670250043005 · Cited by 316
Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis
Nassif, A., Bensussan, A., Bachot, N., Bagot, M., Boumsell, L., Roujeau, J.-C., Dorothée, G., & Mami-Chouaib, F. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01622.x · Cited by 310
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
PAUL, C., WOLKENSTEIN, P., ADLE, H., WECHSLER, J., GARCHON, H. J., REVUZ, J., & ROUJEAU, J. C. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb06976.x · Cited by 304
Genetic Susceptibility to Toxic Epidermal Necrolysis
Roujeau, J. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.9.1171 · Cited by 278
Predisposition to Phenytoin Hepatotoxicity Assessed in Vitro
Spielberg, S. P., Gordon, G. B., Blake, D. A., Goldstein, D. A., & Herlong, H. F. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109243051302 · Cited by 234
Treatment of Toxic Epidermal Necrolysis with Cyclosporin A
Ar??valo, J. M., Lorente, J. A., Gonz??lez-Herrada, C., & Jim??nez-Reyes, J. (2000) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-200003000-00017 · Cited by 212
Correia, O. (1993) · Archives of Dermatology · doi:10.1001/archderm.129.4.466 · Cited by 191
Wolkenstein, P., Carri??re, V., Charue, D., Bastuji-Garin, S., Revuz, J., Roujeau, J.-C., Beaune, P., & Bagot, M. (1995) · Pharmacogenetics · doi:10.1097/00008571-199508000-00011 · Cited by 143
Death Receptors in Cutaneous Biology and Disease
Wehrli, P., Viard, I., Bullani, R. R., French, L. E., & Tschopp, J. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00037.x · Cited by 139
Self-citationPlasmapheresis in Severe Drug-Induced Toxic Epidermal Necrolysis
Kamanabroo, D. (1985) · Archives of Dermatology · doi:10.1001/archderm.1985.01660120074023 · Cited by 131
Viard, I., Bullani, R. R., Meda, P., Micheau, O., Limat, A., Saurat, J. ‐., Tschopp, J., & French, L. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212188200 · Cited by 75
Self-citationLow N‐acetylating capacity in patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis*
Dietrich, A., Kawakubo, Y., Rzany, B., Mockenhaupt, M., Simon, J. C., & Schöpf, E. (1995) · Experimental Dermatology · doi:10.1111/j.1600-0625.1995.tb00211.x · Cited by 60
Cited by
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Epidemiology and risk factors for drug allergy
Thong, B. Y., & Tan, T. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03774.x · Cited by 393
Huang, Y., Wu, C., Chang, T., Peng, C., Lo, G., Hsu, C., Hu, C., & Huang, Y. (2021) · Liver International · doi:10.1111/liv.14990 · Cited by 20
Metadata
- Authors
- French, L. E.
- Venue
- Allergology International
- Publisher
- Japanese Society of Allergology
- Published
- 2006
- Volume
- 55
- Issue
- 1
- Pages
- 9-16
- ISSN
- 1323-8930 (ISSN-L)
- OpenAlex
- W2077955156
- Cited by
- 263
- References
- 30
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.